BrukerBRKR
BRKR
About: Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
Employees: 11,396
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
63% more first-time investments, than exits
New positions opened: 98 | Existing positions closed: 60
19% more repeat investments, than reductions
Existing positions increased: 145 | Existing positions reduced: 122
8% more funds holding
Funds holding: 364 [Q4 2024] → 394 (+30) [Q1 2025]
1.47% less ownership
Funds ownership: 80.85% [Q4 2024] → 79.38% (-1.47%) [Q1 2025]
29% less funds holding in top 10
Funds holding in top 10: 7 [Q4 2024] → 5 (-2) [Q1 2025]
30% less capital invested
Capital invested by funds: $7.19B [Q4 2024] → $5.03B (-$2.16B) [Q1 2025]
54% less call options, than puts
Call options by funds: $6.24M | Put options by funds: $13.6M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$40
4%
upside
Avg. target
$47
24%
upside
High target
$60
57%
upside
6 analyst ratings
2 positive
33%
4 neutral
67%
0 negative
0%
Citigroup Patrick Donnelly | 4%upside $40 | Neutral Downgraded | 22 May 2025 |
UBS Dan Leonard | 17%upside $45 | Neutral Maintained | 8 May 2025 |
Barclays Luke Sergott | 20%upside $46 | Overweight Maintained | 8 May 2025 |
Goldman Sachs Matthew Sykes | 17%upside $45 | Neutral Maintained | 8 May 2025 |
Stifel Daniel Arias | 25%upside $48 | Hold Maintained | 8 May 2025 |
Financial journalist opinion
Based on 10 articles about BRKR published over the past 30 days
Positive
Zacks Investment Research
5 days ago
Bruker Stock Set to Gain From Acquisition of Austria's biocrates
BRKR strengthens its MS-based metabolomics platform with the biocrates deal, boosting investor sentiment.
Neutral
Business Wire
1 week ago
Bruker Applied MS Unveils Strategic Innovations at ASMS 2025, Showcasing Advances in DART Technology for TDM and DoA Analysis and Launching timsMetabo™ for PFAS and Environmental Contaminant Detection
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (NASDAQ: BRKR) today announced that its Applied Mass Spectrometry (Applied MS) division will present a powerful lineup of innovations at the 73rd American Society for Mass Spectrometry (ASMS) Conference, taking place June 1–5, 2025, in Baltimore, Maryland. These developments reflect Bruker's continued investment in applied markets, particularly in therapeutic drug monitoring (TDM), drugs of abuse (DoA) analysis and environmental analysis. Br.
Neutral
Business Wire
1 week ago
Bruker Announces Acquisition of biocrates, a Leader in Mass Spectrometry-based Quantitative Metabolomics
INNSBRUCK, Austria--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (NASDAQ: BRKR) today announced the acquisition of biocrates life sciences ag, located in Innsbruck, Austria. Financial terms were not disclosed. biocrates is a global leader in mass spectrometry (MS)-based quantitative metabolite and lipid analysis kits, assays, software and services that make standardized metabolomics accessible to laboratories worldwide. The biocrates kits cover over 1,000+ metabolites from more than 40 metabolite classe.
Neutral
Business Wire
1 week ago
Bruker Launches New timsUltra AIP System with Further Enhanced, Extreme Sensitivity for Single-Cell Proteomics, FNA Biopsy Immunopeptidomics and Metaproteomics
BALTIMORE--(BUSINESS WIRE)---- $BRKR #BRKR--At the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), Bruker Corporation (Nasdaq: BRKR) today announced significant further advances in ultra-high sensitivity 4D-Proteomics™ with the introduction of the timsUltra AIP mass spectrometer. Its innovative, breakthrough Athena Ion Processor (AIP) technology further boosts the extreme sensitivity of timsTOF Ultra PASEF® methods for key biological and clinical research problems with very low sample amounts. N.
Neutral
Business Wire
1 week ago
Bruker Unveils New proteoElute™ nanoLC System and PepSep® Advanced nLC Columns for up to 50% Improved Peptide Sensitivity
BALTIMORE--(BUSINESS WIRE)---- $BRKR #BRKR--At the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), Bruker Corporation (Nasdaq: BRKR) today announced the new proteoElute nanoLC system, featuring ceramic valves, proteoTrap trapping columns, and next-generation PepSep Advanced nLC columns, further enhancing robustness, sensitivity and proteome coverage in ultra-sensitive proteomics workflows. A. Bruker Introduces the proteoElute Next-Generation Nanoflow LC System for Robust, Ultra-Sensitive Proteom.
Neutral
Business Wire
2 weeks ago
Bruker Corporation to Present at the Jefferies Global Healthcare Conference
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced today that its senior leadership will participate in the Jefferies Global Healthcare Conference in New York City with a fireside chat presentation scheduled for Wednesday, June 4th, 2025 at 5:30 PM Eastern Time. A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. A replay of the presentation will be posted in the “Events &.
Neutral
Business Wire
2 weeks ago
Bruker Launches Revolutionary timsOmniTM Mass Spectrometer
BALTIMORE--(BUSINESS WIRE)---- $BRKR #BRKR--For the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), Bruker Corporation (Nasdaq: BRKR) announced the launch of the timsOmni™ system, a transformative new timsTOF-based mass spectrometer designed for scientific, drug discovery, and clinical researchers, as well as for advanced QC on biologics, offering deep structural insights into the functional or pathological proteoforms or oligonucleotides. Multimodal eXd trapping with precise electron energy con.
Neutral
Business Wire
2 weeks ago
Bruker Launches Novel timsMetabo™ Mass Spectrometer for Breakthrough 4D-Metabolomics and 4D-Lipidomics Sensitivity, Specificity and Annotation Confidence - at Speed, Depth, and Scale
BALTIMORE--(BUSINESS WIRE)---- $BRKR #BRKR--At the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), Bruker Corporation (Nasdaq: BRKR) launched timsMetabo, a peak-performance 4D-Metabolomics™ mass spectrometer delivering unprecedented sensitivity, separation power and annotation confidence for small molecules, further enhanced by the novel TIMS ‘MoRE' scan-mode. The timsMetabo system enables the generation of a ‘digital metabolome archive' for every sample, providing TIMS-enabled qual-quant perfor.
Positive
Zacks Investment Research
2 weeks ago
Bruker Stock to Gain From the Launch of MOVE-T Liquid Dairy Analyzer
BRKR unveils the MOVE-T analyzer to boost quality and efficiency in the dairy industry, setting new standards for precision and reliability.
Neutral
Business Wire
2 weeks ago
Bruker Introduces Novel MOVE-T System for Transferable, Robust Milk and Liquid Dairy Analysis with FT-NIR Technology
ETTLINGEN, Germany--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced the launch of the MOVE-T, a state-of-the-art liquid dairy analyzer designed to elevate quality control standards in the dairy industry. Utilizing advanced Fourier Transform Near-Infrared (FT-NIR) technology, the MOVE-T provides unparalleled precision analyzing raw milk and other liquid dairy products, ensuring superior product quality and consistency. Tailored for the dairy industry and sectors processing liq.
Charts implemented using Lightweight Charts™